Navigation Links
Biomira announces plan to change name to Oncothyreon
Date:9/27/2007

pplication of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to the proposed reincorporation transaction, Biomira's business, the regulatory approval process and the general economic environment. Many of these risks and uncertainties are beyond Biomira's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the completion of the proposed arrangement and reincorporation; the clinical development of Stimuvax, PX-12, PX-478 and PX-866; the therapeutic and commercial potential of Stimuvax, PX-12, PX-478 and PX-866; the filing of an Investigational New Drug application for PX-866 and the timing thereof; future clinical development plans; and the other risks and uncertainties described in the reports and other documents, including the registration statement on Form S-4, filed by either Biomira Inc. or Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Biomira believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Biomira and Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in the amended registration statement on Form S-4 filed by Oncothyreon Inc. with the SEC and on SEDAR.

Additional Information About the Arrangement/Reincorporation and Where to

Find It

On September 27, 2007, Oncothyreon Inc., a Delaware corporation that will, if the arrangement is ap
'/>"/>

SOURCE Biomira Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... - Biomira Inc. (Nasdaq: BIOM ),(TSX: BRA) ... a randomized Phase II trial of the Stimuvax(R) ... results suggest that Stimuvax,combined with best supportive care ... stage IIIB NSCLC who had either responded or ...
... Calif., Sept. 5 Hyperion,Therapeutics, a biopharmaceutical company ... hepatology therapies for the,treatment of Urea Cycle Disorders ... million Series B financing. Leading the round was,Sofinnova ... and,NEA, all of Menlo Park, CA. WRF Capital ...
... 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announced ... Bear Stearns 20th Annual Healthcare Conference on September,11, 2007 ... at the Grand,Hyatt Hotel in New York City. Jack ... provide a corporate overview of the,company and its clinical ...
Cached Biology Technology:Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 2Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 3Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer 4Hyperion Therapeutics Secures $40 Million In Series B Round 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... starfish to carry out one of the most remarkable forms ... by first extending its stomach out of its mouth and ... and clams. The prey tissue is partially digested externally before ... digestive glands. , The researchers at Queen Mary, University of ...
... article published in this month,s issue of Pediatrics ... Medicine (BUSM) stress the importance of physicians recognizing that ... to make accurate health assessments for both mother and ... guidelines set a standardized risk assessment of herbal supplement ...
... will present the Society,s highest honor, the 2013 Wallace ... Professor Sir David Weatherall, MD, of the University of ... combining seminal discoveries, visionary translational research leadership, and a ... improve clinical care for thousands throughout the developing world. ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2Study finds physicians need to better recognize use of herbal supplements while breastfeeding 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 3Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 4
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Request Info...
Mouse Limitin MAb (Clone 183727)...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Biology Products: